Search results
Results from the WOW.Com Content Network
Drug-induced liver injury (DILI) is a cause of acute and chronic liver disease caused specifically by medications and the most common reason for a drug to be withdrawn from the market after approval. The liver plays a central role in transforming and clearing chemicals and is susceptible to the toxicity from these agents.
Hy's law is a rule of thumb that a patient is at high risk of a fatal drug-induced liver injury if given a medication that causes hepatocellular injury (not Hepatobiliary injury) with jaundice. [1] The law is based on observations by Hy Zimmerman, a major scholar of drug-induced liver injury.
NAPQI, also known as NAPBQI or N-acetyl-p-benzoquinone imine, is a toxic byproduct produced during the xenobiotic metabolism of the analgesic paracetamol (acetaminophen). [1] It is normally produced only in small amounts, and then almost immediately detoxified in the liver.
Analogous terms such as "drug-induced" or "toxic" liver disease are also used to refer to disorders caused by various drugs. [7] Fatty liver disease (hepatic steatosis) is a reversible condition where large vacuoles of triglyceride fat accumulate in liver cells. [8]
Pyrrolizidine alkaloidosis can result in damage to the liver, kidneys, heart, brain, smooth muscles, lungs, DNA, lesions all over the body, and could be a potential cause of cancer. [ 1 ] [ 2 ] Pyrrolizidine alkaloidosis is known by many other names such as "Pictou Disease" in Canada [ 3 ] and "Winton Disease" in New Zealand. [ 4 ]
The US Food and Drug Administration has approved the first medication for a common form of liver inflammation called nonalcoholic steatohepatitis, or NASH, the agency said Thursday.
By Leroy Leo (Reuters) -Akero Therapeutics said its lead drug to treat patients with a severe type of fatty liver disease missed the main goal in a mid-stage trial, sending its shares tumbling 60% ...
(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' liver disease treatment, Livdelzi, which it gained through a $4.3 billion buyout of CymaBay Therapeutics ...